Oncternal Therapeutics Stock Z Score
ONCT Stock | USD 8.60 0.06 0.69% |
Oncternal | Z Score |
Oncternal Therapeutics Company Z Score Analysis
Oncternal Therapeutics' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Oncternal Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Oncternal Therapeutics is extremely important. It helps to project a fair market value of Oncternal Stock properly, considering its historical fundamentals such as Z Score. Since Oncternal Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Oncternal Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Oncternal Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
Competition |
Based on the company's disclosures, Oncternal Therapeutics has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Oncternal Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oncternal Therapeutics' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Oncternal Therapeutics could also be used in its relative valuation, which is a method of valuing Oncternal Therapeutics by comparing valuation metrics of similar companies.Oncternal Therapeutics is currently under evaluation in z score category among related companies.
Oncternal Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Oncternal Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Oncternal Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Oncternal Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Oncternal Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Oncternal Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Oncternal Therapeutics' value.Shares | Axxcess Wealth Management, Llc | 2023-12-31 | 70.4 K | Two Sigma Securities, Llc | 2023-12-31 | 58.8 K | Regents Of The University Of California | 2023-12-31 | 53.6 K | Balboa Wealth Partners | 2023-12-31 | 47.5 K | Creative Planning Inc | 2023-12-31 | 39.3 K | Beta Wealth Group, Inc | 2023-12-31 | 32 K | Dimensional Fund Advisors, Inc. | 2024-03-31 | 25.9 K | Richmond Brothers Inc | 2024-03-31 | 24.7 K | Valeo Financial Advisors, Llc | 2023-12-31 | 23.5 K | Blackrock Inc | 2023-12-31 | 785.7 K | Renaissance Technologies Corp | 2023-12-31 | 327.2 K |
Oncternal Fundamentals
Return On Equity | -0.87 | ||||
Return On Asset | -0.49 | ||||
Operating Margin | (15.43) % | ||||
Current Valuation | (8.31 M) | ||||
Shares Outstanding | 2.96 M | ||||
Shares Owned By Insiders | 9.23 % | ||||
Shares Owned By Institutions | 15.57 % | ||||
Number Of Shares Shorted | 12.95 K | ||||
Price To Earning | (37.77) X | ||||
Price To Book | 0.93 X | ||||
Price To Sales | 35.44 X | ||||
Revenue | 785 K | ||||
Gross Profit | (31.49 M) | ||||
EBITDA | (41.71 M) | ||||
Net Income | (39.48 M) | ||||
Cash And Equivalents | 78.9 M | ||||
Cash Per Share | 1.48 X | ||||
Total Debt | 318 K | ||||
Debt To Equity | 0 % | ||||
Current Ratio | 10.78 X | ||||
Book Value Per Share | 10.19 X | ||||
Cash Flow From Operations | (32.16 M) | ||||
Short Ratio | 2.11 X | ||||
Earnings Per Share | (12.33) X | ||||
Target Price | 27.67 | ||||
Number Of Employees | 27 | ||||
Beta | 1.36 | ||||
Market Capitalization | 25.63 M | ||||
Total Asset | 36.73 M | ||||
Retained Earnings | (197.78 M) | ||||
Working Capital | 30.86 M | ||||
Current Asset | 27.27 M | ||||
Current Liabilities | 6.3 M | ||||
Net Asset | 36.73 M |
About Oncternal Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oncternal Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncternal Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncternal Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Oncternal Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Oncternal Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Oncternal Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Oncternal Therapeutics Stock: Check out Oncternal Therapeutics Piotroski F Score and Oncternal Therapeutics Valuation analysis. For more information on how to buy Oncternal Stock please use our How to Invest in Oncternal Therapeutics guide.Note that the Oncternal Therapeutics information on this page should be used as a complementary analysis to other Oncternal Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Complementary Tools for Oncternal Stock analysis
When running Oncternal Therapeutics' price analysis, check to measure Oncternal Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncternal Therapeutics is operating at the current time. Most of Oncternal Therapeutics' value examination focuses on studying past and present price action to predict the probability of Oncternal Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncternal Therapeutics' price. Additionally, you may evaluate how the addition of Oncternal Therapeutics to your portfolios can decrease your overall portfolio volatility.
Transaction History View history of all your transactions and understand their impact on performance | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories |
Is Oncternal Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncternal Therapeutics. If investors know Oncternal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncternal Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (12.33) | Revenue Per Share 0.39 | Quarterly Revenue Growth 1.803 | Return On Assets (0.49) | Return On Equity (0.87) |
The market value of Oncternal Therapeutics is measured differently than its book value, which is the value of Oncternal that is recorded on the company's balance sheet. Investors also form their own opinion of Oncternal Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Oncternal Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncternal Therapeutics' market value can be influenced by many factors that don't directly affect Oncternal Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oncternal Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncternal Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncternal Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.